# Longmen Capital

> Longmen Capital is a VC fund in Shenzhen backing Health Care and Biotechnology. See 22 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 22
- Last investment: Aug 2026
- Lead investor: 18%
- Last updated: Aug 2026
- Website: https://www.longmencapital.com/

Longmen Capital is a private equity firm focused on investing in the medical sector. The Shenzhen, Guangdong-headquartered firm was founded in 2017.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 50% |
| Biotechnology | 8 | 36% |
| Medical | 7 | 32% |
| Pharmaceutical | 5 | 23% |
| Biopharma | 3 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 32% |
| Series B | 5 | 23% |
| Seed | 3 | 14% |
| Series C | 2 | 9% |
| Series D | 2 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 16 | 73% |
| United States | 2 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hopstem | Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering. | $29.6M | Series C | Aug 10, 2026 |  |
| Ractigen Therapeutics | Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation(RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need. | $31M | Venture - Series Unknown | Jul 29, 2026 |  |
| Kinco Biotechnology | Kinco Biotech is a gene therapy product developer that develops platforms for gene therapy research and development, including viral vector construction and optimization, large-scale cell culture and virus production processes, quality control systems, and preclinical validation. |  | Series A | Dec 01, 2025 |  |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. |  | Series A | Jan 22, 2025 |  |
| Crystal Egg Bio | Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise.The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs. | $1.4M | Series A | Sep 13, 2024 |  |
| Innovo Therapeutics | Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown. | $14.1M | Seed | Dec 01, 2023 |  |
| ICE Bioscience | ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14M | Series B | Sep 26, 2022 |  |
| Kaidi Medical | Kaidi Medical is a developer of tumor immunotherapy drugs. | $15.8M | Series A | Mar 10, 2022 |  |
| Crystal Egg Bio | Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise.The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs. |  | Seed | Jan 07, 2022 |  |
| QureBio | QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug developmentincluding phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform.The company was founded in 2017 and is based in Pudong District, Shanghai. | $31.3M | Series B | Dec 24, 2021 |  |

10 of 22 investments shown.

## Co-investors
- [Lotus Lake Ventures](https://shizune.co/investors/profile/lotus-lake-ventures) — VC Fund, 3 deals together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 2 deals together
- [BOCOM International](https://shizune.co/investors/profile/bocom-international) — VC Fund, 2 deals together
- [Guangdong Technology Financial Group](https://shizune.co/investors/profile/guangdong-technology-financial-group) — VC Fund, 2 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 2 deals together
- [Oriza Holdings](https://shizune.co/investors/profile/oriza-holdings) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Longmen Capital invest in?

Longmen Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 22 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Longmen Capital last invest?

The most recent investment recorded for Longmen Capital closed in Aug 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co